CD8A and neoplasm: Data show a greater benefit in tumors that were both PD-L1 and CD8 positive, which suggests that patients with an ‘inflamed’ tumor phenotype might be the population in which further exploration of ICIs is warranted, despite being a minority of patients with recurrent EOC [41].